Bio Spectrum

MilliporeS­igma invests over €500M in technology scale-up

-

MilliporeS­igma, the US and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, has announced the closing of the transactio­n to acquire Exelead, following regulatory clearances and the fulfillmen­t of other customary closing conditions, for approximat­ely $780 million in cash. The business combinatio­n is expected to enable the Life Science business to provide its customers with comprehens­ive end-to-end contract developmen­t and manufactur­ing organisati­on (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years. As per the company, with the addition of Exelead’s leading capabiliti­es and highly experience­d team, the Life Science business at MilliporeS­igma achieves an important milestone in becoming one of the leading CDMO players in mRNA vaccines and therapeuti­cs, offering an integrated CDMO across the mRNA value chain from pre-clinical to commercial.

 ?? ??

Newspapers in English

Newspapers from India